Company intelligence / Profile preview
Neuronity Therapeutics
Mansfield, Massachusetts, United Statesneuronitytx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neuronity Therapeutics is an active biotech startup founded in Massachusetts in 2022 that develops first-in-class immunotherapies targeting age-related neurodegenerative diseases such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy. Their innovative approach focuses on boosting the brain's natural immunity by engineering or pharmacologically transforming central nervous system-resident or blood-derived immune cells to clear toxic alpha-synuclein protein aggregates responsible for synucleinopathies.
- Therapeutic areas
- Neurology
- Modalities
- Immune cell engineeringGene and cell therapyPharmacological agents transforming CNS immune cellsAdoptive Cell Therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Neuronity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuronity Therapeutics.